Mwandishi:
Dkt. Mercy M, CO
Mhariri:
Dkt. Benjamin L, MD
Ibandronate ni dawa kizazi cha tatu cha bisphosphonate yenye nitrogen inayotumika kukinga na kutibu magonjwa ya mifupa dhaifu kwa wanawake walio kwenye komahedhi.
Majina ya kibiashara ya Ibandronate
Majina mengine ya Ibandronate ni;
Bovina
Bondronat
Boniva
Iasibon
Ibandronate hufahamika pia kama;
Ibandronate monosodium monohydrate
Ibandronate sodium
Ibandronate sodium hydrate
Ibandronate sodium monohydrate
Ibandronic acid (as sodium ibandronate)
Ibandronic acid sodium salt
Ibandronic acid sodium salt monohydrate
Ibandronic sodium monohydrate
Sodium ibandronate
Dawa zilizo kundi moja na Ibandronate
Dawa zilizo kundi moja na Ibandronate ni ;
Risedronate
Etidronate
Alendronate
Pamidronate
Zoledronate
Fomu na uzito wa Ibandronate
Ibandronate ina uzito ufuatao;
Kidonge chenye uzito wa 150mg
Kimiminika cha kuchoma kwa sindano chenye uzito wa 1mg/1ml (3ml)
Ibandronate hutibu nini?
Hutumika kutibu udhaifu wa mifupa kwa wanawake walio koma hedhi
Hutumika kukinga udhaifu wa mifupa kwa wanawake walio koma hedhi
Namna Ibandronate inavyoweza kufanya kazi
Mara baada ya kuingia kwenye damu ibandronate acid hujishikiza kwenye hydroxyapatite ya mifupa. Ufyonzwaji kalisiamu kwenye mifupa hutengeneza mazingira ya utindikali katika mifupa na kupelekea kuachiwa kwa ibandronate acid kutoka kwenye mifupa. Ibandronate acid hufyonzwa na chembe osteoclasts kisha kuachiwa kwenye saitosol ya osteoclasts inayofanya kazi ya kufyonza mifupa. Kuzuiwa ufanyaji kazi wa osteoclasts husababisha kupungua kwa ufyonzwaji wa kalisiiamu ndani ya mifupa na hivyo kufanya mifupa iwe imara kutokana na kutopoteza madini hayo.
Ufyonzwaji wa dawa
Asilimia 0.63 ya dawa hufyonzwa na kuingia kwenye damu kama ikitumika kwa kunywa.
Mwingiliano wa Ibandronate na chakula
Ili kutopunguza ufyonzwaji wa dawa hii, kunywa kwa kutumia maji tu na si vimiminika vya aina nyingine au juisi. Tumia pasipo chakula maana chakula pia hupunguza ufyonzwaji wake
Wagonjwa wasiopaswa kutumia Ibandronate
Wagonjwa wenye mzio wa Ibandronate.
Wagonjwa wenye mzio wa dawa jamii ya bisphosphonate derivatives.
Utoaji taka wa Ibandronate mwilini
Asilimia hamsini hadi sitini (50%-60%) hutolewa kwa njia ya mkojo, dawa ambayo haijafyonzwa hutolewa mwilini kupitia kinyesi.
Matumizi ya Ibandronate kwa mama mjamzito
Dawa hii hairuhusiwi kwa wanawake walio katika umri wa kuzaa. Hakuna tafiti zinazoonesha madhara ya dawa kwa mama mjamzito na kwa mtoto aliye tumboni hivyo hairuhusiwi kwa mama mjamzito.
Matumizi ya Ibandronate mama anayenyonyesha
Dawa hii hairuhusiwi kwa wanawake walio katika umri wa kuzaa. Hakuna tafiti zinazoonesha madhara ya dawa hii kwa mama anayenyonyesha, kwa mtoto na katika uzalishwaji wa maziwa hivyo hairuhusiwi kutumiwa na mama anayenyonysha.
Dawa zenye muingiliano na Ibandronate
Dawa zenye mwingiliano mkali na hivyo kutofaa kutumika pamoja na Ibandronate;
Hakuna Orodha ya dawa yenye muingiliano mkali na Ibandronate.
Dawa zinazoweza kutumika na Ibandronate chini ya uangalizi;
Aluminum hydroxide
Calcium acetate
Calcium carbonate
Calcium chloride
Calcium citrate
Calcium gluconate
Carbonyl iron
Deferasirox
Ferric maltol
Ferrous fumarate
Ferrous gluconate
Ferrous sulfate
Iron dextran complex
Iron sucrose
Magnesium supplement
Polysaccharide iron
Rose hips
Selenium
Sodium bicarbonate
Sodium citrate/citric acid
Sodium sulfate/?magnesium sulfate/potassium chloride
Sodium sulfate/potassium sulfate/magnesium sulfate
Voclosporin
Zinc
Dawa zenye mwingiliano mdogo na Ibandronate;
Entecavir
Foscarnet
Magnesium chloride
Magnesium citrate
Magnesium hydroxide
Magnesium oxide
Magnesium sulfate
Teriparatide
Maudhi ya Ibandronate
Maumivu ya tumbo
Maumivu ya kichwa
Maumivu ya mifupa, misuli na viungio vya mwili
Degedege
Homa
Mgongo kuuma
Kizunguzungu
Nimonia
Kuharisha
Bronchaitiz
Maambukizi kwenye mfumo wa juu wa hewa
Ufanye nini endapo utasahau kutumia dozi yako?
Ni muhimu sana kutumia dozi yako kwa wakati sahihi. Kama umesahau kutumia dozi kwa wakati sahihi wasiliana na daktari ili aweze kukupangia muda sahihi wa kutumia dozi inayofata.
13 Juni 2023 19:18:46
Dawa Ibandronate
Imeboreshwa,
24 Septemba 2021 18:15:33
Dawa yoyote ni sumu, usitumie dawa pasipo ushauri wa daktari kuepuka madhara kwenye ogani mbalimbali kama figo na ini. Matumizi ya dawa pasipo ushauri wa daktari unaweza kusababisha madhara na usugu wa vimelea vya maradhi kwenye dawa.
ULY CLINIC inakushauri siku zote uwasiliane na daktari wako kwa ushauri na tiba kabla ya kuchukua hatua yoyote ile baad aya kusoma makala hii.
Kupata ushauri zaidi na tiba kutoka kwa daktari wa ULY CLINIC bofya Mawasiliano yetu au Pata tiba.
Rejea za mada hii:
Bäck SE, et al. Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab Invest. 1989 Nov;49(7):641–646.
Bax RP, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):311–320.
Burman LA, et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother. 1991 Feb;27(2):219–224.
Christensson BA, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532–1537.
DAVIES DF, SHOCK NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950 May;29(5):496–507.
Douglas JG, et al. The pharmacokinetics of cefuroxime in the elderly. J Antimicrob Chemother. 1980 Jul;6(4):543–549.
Granerus G, et al. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest. 1981 Oct;41(6):611–616.
Harrison MP, et al. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):265–277.
Jones RN, et al. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 (Suppl A):9–29.
Krutzén E, et al. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med. 1984 Dec;104(6):955–961.
Ljungberg B, et al. Pharmacokinetics of antimicrobial agents in the elderly. Rev Infect Dis. 1987 Mar-Apr;9(2):250–264.